Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen
Open Access
- 12 December 2019
- journal article
- research article
- Published by Taylor & Francis in mAbs
- Vol. 12 (1) , 1690959
Abstract
Complement-dependent cytotoxicity (CDC) is a potent effector mechanism, engaging both innate and adaptive immunity. Although strategies to improve the CDC activity of antibody therapeutics have primarily focused on enhancing the interaction between the antibody crystallizable fragment (Fc) and the first subcomponent of the C1 complement complex (C1q), the relative importance of intrinsic affinity and binding valency of an antibody to the target antigen is poorly understood. Here we show that antibody binding affinity to a cell surface target antigen evidently affects the extent and efficacy of antibody-mediated complement activation. We further report the fundamental role of antibody binding valency in the capacity to recruit C1q and regulate CDC. More specifically, an array of affinity-modulated variants and functionally monovalent bispecific derivatives of high-affinity anti-epidermal growth factor receptor (EGFR) and anti-human epidermal growth factor receptor 2 (HER2) therapeutic immunoglobulin Gs (IgGs), previously reported to be deficient in mediating complement activation, were tested for their ability to bind C1q by biolayer interferometry using antigen-loaded biosensors and to exert CDC against a panel of EGFR and HER2 tumor cells of various histological origins. Significantly, affinity-reduced variants or monovalent derivatives, but not their high-affinity bivalent IgG counterparts, induced near-complete cell cytotoxicity in tumor cell lines that had formerly been shown to be resistant to complement-mediated attack. Our findings suggest that monovalent target engagement may contribute to an optimal geometrical positioning of the antibody Fc to engage C1q and deploy the complement pathway.Keywords
This publication has 66 references indexed in Scilit:
- Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functionsMethods, 2014
- Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain BarrierScience Translational Medicine, 2013
- Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRsThe Journal of Immunology, 2013
- New Insights of an Old Defense System: Structure, Function, and Clinical Relevance of the Complement SystemMolecular Medicine, 2010
- Terminal sugars of Fc glycans influence antibody effector functions of IgGsCurrent Opinion in Immunology, 2008
- Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic ActivitiesCancer Research, 2008
- Complement driven by conformational changesNature Reviews Immunology, 2008
- Potent antibody therapeutics by designNature Reviews Immunology, 2006
- Complement Activated by Chimeric Anti–Folate Receptor Antibodies Is an Efficient Effector System to Control Ovarian CarcinomaCancer Research, 2006
- Reaction between the isolated globular sub-units of the complement component Clq and IgG-complexesMolecular Immunology, 1979